Medicine
Savella 50 mg tablet
Savella 50 mg tablet is a prescription medicine containing Milnacipran for oral use, marketed by Allergan, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted between 15°C and 30°C (between 59°F…
Key facts
- Active ingredient (INN)
- Milnacipran
- Brand
- Savella
- Strength
- 50 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 60 tablets, 1920 tablets
- Marketing authorisation holder
- Allergan
- Manufacturers
- AllerganCardinal Health
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06AX17 Milnacipran
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 April 2009
- Identifiers
- RxCUI 833144, 833146, 833135 +7DailyMed set ID 8b720a1e-034b-4583-b80d-105a794cce74, 16a4a314-f97e-4e91-95e9-576a3773d284NDC 55154-4626, 0456-1550Application NDA022256
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet, film coated in 1 bottle | 0456-1550-60 | Allergan | 17 April 2009 |
| 1920 tablet, film coated in 1 bottle | 55154-4626-8 | Cardinal Health | 17 April 2009 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 14 January 2009 | Drugs@FDA |
| EU (EMA) | Refused | EMA medicines data |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Milnacipran 50 mg tablet.
Other strengths and forms of Milnacipran
Clinical summary
Milnacipran is a serotonin and norepinephrine reuptake inhibitor indicated for the management of fibromyalgia, among other approved uses. It is available as tablets and kits for oral use. MedsAcross supplies Milnacipran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MilnacipranFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Milnacipran Hydrochloride prescribing information (Glenmark Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Savella 50 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.